



Press release from Emotra AB (publ)

Göteborg, October 24, 2014

## Lars-Håkan Thorell appointed as President of World Suicidology Net.

**Lars-Håkan Thorell, the inventor of EDOR and Emotra's research manager, has been appointed as President of the global organisation World Suicidology Net. This organisation has several hundred members and is represented in more than 50 countries around the world. The organisation's objective is to spread information about research in suicide prevention and other suicide-related issues.**

Being appointed to this position is a great honour and the creator of EDOR has accepted it. The motivation for this appointment is his many years of research which have resulted in EDOR, a diagnostics method for evaluating a patient's suicide risk. This new assignment is an international recognition of Lars-Håkan Thorell's research, which has led to a clinically feasible diagnostics method, which at present is undergoing clinical trials in ten European countries.

This appointment does not conflict with Lars-Håkan Thorell's responsibilities as Emotra's research manager. The Company is convinced that the presidency of World Suicidology Net, even if it will take up some of Thorell's available time, will lead to the establishment of many valuable contacts with researchers outside Europe, which naturally also strengthens our relationships with leading researchers in Europe. This also reinforces the credibility for both EDOR and Lars-Håkan Thorell's research and should have a decisive effect when the time comes to launch Emotra on the international market.

Emotra's method continues to gather interest and commitment among leading researchers in suicide prevention. Special symposiums on the method are being arranged in connection with international psychiatric conventions. Lars-Håkan Thorell and other involved people are holding more and more presentations about the method at psychiatric conventions. However, this does not change the fact that the ongoing multi-centre study needs to be completed so that we can prove the method is safe, reliable, effective and user-friendly. Achieving this will lay the groundwork for a successful market launch of EDOR.

**For further information, please contact:**

*Claes Holmberg, CEO*

*Telephone: +46 708 25 45 47*

*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

---

*Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*